Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Clin Exp Pharmacol Physiol ; 46(5): 427-434, 2019 05.
Article in English | MEDLINE | ID: mdl-30697784

ABSTRACT

Many hypertensive animal models have been developed and used to elucidate the pathophysiology of hypertension and to develop antihypertensive drugs. Among them, the spontaneous hypertensive rat (SHR), deoxycorticosterone acetate (DOCA)-treated and high salt intake rat (DOCA-salt), and high sodium-fed Dahl salt-sensitive rat (HS) models are commonly used. Multiple studies have been conducted, however, elevation in blood pressure in these models due to the reactivity of adrenergic vasoconstriction has not been well characterized in a centralized experiment. In this study, the pressor responses to periarterial nerve stimulation (PNS) or exogenous noradrenaline (NA) infusion were measured in the isolated mesenteric vascular bed with the intestinal tract to investigate the reactivity of mesenteric adrenergic vasoconstriction. The systemic arterial blood pressure of the hypertensive rat models was uniformly elevated compared with their respective controls. However, the changes in perfusion pressure in the mesenteric vascular bed in response to PNS and exogenous NA infusion were quite different depending on the model. The pressor responses to PNS in SHRs and Dahl S HS rats were significantly higher, and those in DOCA-salt rats were significantly lower than those in the controls. The pressor responses to exogenous NA infusion in SHRs were significantly higher, and those in Dahl S HS rats were significantly lower than those in their respective controls. No difference was observed in the pressor responses to the exogenous NA between the DOCA-salt and sham groups. These results demonstrate that the reactivity of adrenergic vasoconstriction is different for each type of experimental hypertensive model rat.


Subject(s)
Electric Stimulation Therapy , Hypertension/therapy , Intestines/blood supply , Mesentery/drug effects , Norepinephrine/pharmacology , Animals , Blood Pressure/drug effects , Disease Models, Animal , Hypertension/drug therapy , Hypertension/physiopathology , Male , Mesentery/physiopathology , Norepinephrine/administration & dosage , Norepinephrine/therapeutic use , Rats
2.
Food Funct ; 2(7): 386-94, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21894325

ABSTRACT

Deposition of amyloid ß peptide (Aß) into the brain causes cognitive impairment. We investigated whether prescription pre-administration of n-3 fatty acids improves cognitive learning ability in young rats and whether it protects against learning ability impairments in an animal model of Alzheimer's disease that was prepared by infusion of Aß(1-40) into the cerebral ventricles of rats. Pre-administration of TAK-085 (highly purified and concentrated n-3 fatty acids containing eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester) at 300 mg kg(-1) day(-1) for 12 weeks significantly reduced the number of reference memory errors in an 8-arm radial maze, suggesting that long-term administration of TAK-085 improves cognitive leaning ability in rats. After pre-administration, the control group was divided into the vehicle and Aß-infused groups, whereas the TAK-085 pre-administration group was divided into the TAK-085 and TAK-085 + Aß groups (TAK-085-pre-administered Aß-infused rats). Aß(1-40) or vehicle was infused into the cerebral ventricle using a mini osmotic pump. Pre-administration of TAK-085 to the Aß-infused rats significantly suppressed the number of reference and working memory errors and decreased the levels of lipid peroxide and reactive oxygen species in the cerebral cortex and hippocampus of Aß-infused rats, suggesting that TAK-085 increases antioxidative defenses. The present study suggests that long-term administration of TAK-085 is a possible therapeutic agent for protecting against Alzheimer's disease-induced learning deficiencies.


Subject(s)
Amyloid beta-Peptides/administration & dosage , Cognition Disorders/chemically induced , Cognition Disorders/prevention & control , Fatty Acids, Omega-3/administration & dosage , Alzheimer Disease/prevention & control , Animals , Cerebral Cortex/chemistry , Cerebral Cortex/drug effects , Cerebral Ventricles/drug effects , Docosahexaenoic Acids/administration & dosage , Drug Combinations , Eicosapentaenoic Acid/administration & dosage , Eicosapentaenoic Acid/analogs & derivatives , Fatty Acids/blood , Hippocampus/chemistry , Hippocampus/drug effects , Lipid Peroxides/analysis , Male , Maze Learning/drug effects , Rats , Rats, Wistar , Reactive Oxygen Species/analysis
SELECTION OF CITATIONS
SEARCH DETAIL